RESECTABILITY OF COLORECTAL LIVER METASTASES (CLM) WITH CETUXIMAB PLUS CPT-11/5-FLUOROURACIL (5-FU)/LEUCOVORIN(FA)/OXALIPLATIN (L-OHP) (CPT-11-FFL) AS NEOADJUVANT TREATMENT (POCHER TRIAL)

被引：0
|
作者：
Torsello, A.
Garufi, C.
Tumolo, S.
Melucci, E.
Conti, S.
Campanella, C.
Zeuli, M.
Pizzi, G.
Tropea, G.
Sperduti, I
Ettorre, G. M.
Cognetti, F.
机构：
[1] Ist Regina Elena, I-00161 Rome, Italy
[2] Osped SM Angeli, Pordenone, Italy
[3] Osped S Camillo Roma, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase I study of CPT-11 plus chronomodulated (chrono) 5-Fluorouracil (5-FU) and L-folinic acid (FA) in advanced colorectal cancer (ACC) patients
    Garufi, C
    Tampellini, M
    D'Attino, RM
    Nistico, C
    Aschelter, AM
    Pugliese, P
    Caterino, M
    Giunta, S
    Faranda, A
    Tropea, F
    Comis, S
    Dogliotti, L
    Terzoli, E
    ANNALS OF ONCOLOGY, 1998, 9 : 37 - 37
  • [22] Cetuximab plus capecitabine (CAP) and oxaliplatin (LOHP) as salvage treatment for patients with metastatic colorectal cancer (CRC) relapsing after combination chemotherapy including oxaliplatin, irinotecan (CPT-11), and 5-fluorouracil (5-FU) or capecitabine
    Souglakos, J
    Androulakis, N
    Kalykaki, A
    Saridaki, Z
    Vardakis, N
    Kalbakis, K
    Agelaki, S
    Vamvakas, L
    Kentepozidis, N
    Giassas, S
    Mavroudis, D
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2005, 16 : 41 - 41
  • [23] Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
    Van Cutsem, E
    Cunningham, D
    Huinink, WWT
    Punt, CJA
    Alexopoulos, CG
    Dirix, L
    Symann, M
    Blijham, GH
    Cholet, P
    Fillet, G
    Van Groeningen, C
    Vannetzel, JM
    Levi, F
    Panagos, G
    Unger, C
    Wils, J
    Cote, C
    Blanc, C
    Hérait, P
    Bleiberg, H
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (01) : 54 - 59
  • [24] Biweekly administration of irinotecan (CPT-11), oxaliplatin (OX) and 5-fluorouracil (5-FU) as first-line treatment of advanced or metastatic colorectal cancer (MCRC)
    Reina, JJ
    Sánchez-Rovira, P
    Bernabé, R
    Bolaños, M
    González, E
    Belón, J
    Gómez-Reina, MJ
    Gallurt, P
    Moreno-Nogueira, JA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 260S - 260S
  • [25] Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU):: A phase II study
    Antón, A
    Aranda, E
    Carrato, A
    Marcuello, E
    Massutti, B
    Cervantes, A
    Abad, A
    Sastre, J
    Fenández-Martos, C
    Gallén, M
    Díaz-Rubio, E
    Huarte, L
    Balcells, M
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2003, 25 (08): : 639 - 643
  • [26] Pilot trial of 5-FU/oxaliplatin (CIFOX) for patients with metastatic colorectal cancer who progressed on 5-FU/LV/CPT-11 (IFL).
    Aparicio, A
    Iqbal, S
    Yang, D
    Groshen, S
    Park, D
    Garcia, A
    Lenz, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 312S - 312S
  • [27] BIMONTHLY CHEMOTHERAPY (CHT) WITH OXALIPLATIN (OHP), IRINOTECAN (CPT11), INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID (FU/FA) IN PATIENTS WITH METASTATIC COLORECTAL CANCER PRETREATED WITH CPT11-OR OHP-BASED CHT
    Nobili, S.
    Del Buono, S.
    Mazzocchi, V.
    Filippelli, F.
    Checcacci, D.
    Giglioni, B.
    Mazzei, T.
    Mini, E.
    ANNALS OF ONCOLOGY, 2004, 15 : 65 - 65
  • [28] A phase II study with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) in patients with metastatic colorectal cancer
    Destefanis, M
    Dalla Mola, A
    Ostellino, O
    Capello, C
    Milanesi, E
    Grillo, C
    Castiglione, F
    Venturino, A
    Porcile, G
    ANNALS OF ONCOLOGY, 2000, 11 : 67 - 67
  • [29] Phase I study of CPT-11 and bolus 5-FU/l-leucovorin in patients with metastatic colorectal cancer
    Fujishima H.
    Kikuchi I.
    Miyanaga O.
    Ueda A.
    Baba E.
    Mitsugi K.
    Harada M.
    Nakano S.
    International Journal of Clinical Oncology, 2004, 9 (2) : 92 - 97
  • [30] A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma
    Kalofonos, HP
    Skarlos, D
    Bafaloukos, D
    Papakostas, P
    Bamias, A
    Janinis, J
    Timotheadou, E
    Kouvatseas, G
    Stavropoulos, M
    Economopulos, T
    Fountzilas, G
    CANCER INVESTIGATION, 2003, 21 (06) : 855 - 862
12345